BNP Paribas Financial Markets Lowers Stock Holdings in ICU Medical, Inc. (NASDAQ:ICUI)

BNP Paribas Financial Markets trimmed its holdings in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 39.9% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 4,205 shares of the medical instruments supplier’s stock after selling 2,792 shares during the period. BNP Paribas Financial Markets’ holdings in ICU Medical were worth $652,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. Vanguard Group Inc. raised its holdings in ICU Medical by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 2,682,065 shares of the medical instruments supplier’s stock worth $416,176,000 after acquiring an additional 17,805 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in ICU Medical by 7.4% in the 4th quarter. JPMorgan Chase & Co. now owns 708,382 shares of the medical instruments supplier’s stock worth $109,920,000 after acquiring an additional 49,108 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in ICU Medical by 18.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 539,981 shares of the medical instruments supplier’s stock worth $83,788,000 after acquiring an additional 82,982 shares during the last quarter. Northern Trust Corp raised its holdings in ICU Medical by 11.1% in the 4th quarter. Northern Trust Corp now owns 402,342 shares of the medical instruments supplier’s stock worth $62,431,000 after acquiring an additional 40,187 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in ICU Medical by 1.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 304,155 shares of the medical instruments supplier’s stock worth $47,196,000 after acquiring an additional 3,048 shares during the last quarter. 96.10% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Raymond James reduced their price objective on ICU Medical from $197.00 to $187.00 and set a “strong-buy” rating for the company in a research note on Friday, May 9th. Wall Street Zen raised shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Sunday, May 18th. KeyCorp decreased their target price on shares of ICU Medical from $209.00 to $191.00 and set an “overweight” rating on the stock in a research report on Monday, April 21st. Finally, Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a research report on Tuesday, April 8th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $192.67.

Insider Activity

In related news, Director David C. Greenberg sold 1,942 shares of the business’s stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $143.66, for a total transaction of $278,987.72. Following the transaction, the director now directly owns 6,760 shares in the company, valued at approximately $971,141.60. The trade was a 22.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Ben Sousa sold 2,000 shares of the business’s stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $137.36, for a total transaction of $274,720.00. Following the transaction, the insider now owns 479 shares in the company, valued at $65,795.44. The trade was a 80.68% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 26,167 shares of company stock worth $3,571,788 over the last 90 days. 1.50% of the stock is currently owned by company insiders.

ICU Medical Stock Down 1.3%

ICUI opened at $128.99 on Friday. The company has a fifty day moving average of $139.66 and a two-hundred day moving average of $152.73. ICU Medical, Inc. has a fifty-two week low of $100.91 and a fifty-two week high of $196.26. The stock has a market capitalization of $3.17 billion, a price-to-earnings ratio of -28.23 and a beta of 0.87. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.03 and a current ratio of 2.29.

ICU Medical (NASDAQ:ICUI) last announced its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.49. ICU Medical had a negative net margin of 4.74% and a positive return on equity of 5.05%. The business had revenue of $599.49 million for the quarter, compared to analyst estimates of $574.15 million. During the same quarter last year, the business earned $0.96 earnings per share. The company’s revenue for the quarter was up 6.7% compared to the same quarter last year. On average, research analysts expect that ICU Medical, Inc. will post 4.11 earnings per share for the current year.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.